Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11291732 Compounds for degrading α-synuclein aggregates and uses thereof

Patent 11291732 was granted and assigned to Aprinoia Therapeutics on April, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Current Assignee

Aprinoia Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

April 5, 2022

Patent Application Number

17320913

Date Filed

May 14, 2021

Patent Citations

US Patent 10604516 Compounds for imaging tau proteins that accumulate in the brain

US Patent 10669253 Methods to induce targeted protein degradation through bifunctional molecules

US Patent 10772962 Compounds and methods for the targeted degradation of bromodomain-containing proteins

US Patent 10730870 Compounds and methods for the enhanced degradation of targeted proteins

US Patent 10849980 Methods to induce targeted protein degradation through bifunctional molecules

US Patent 10125114 Methods to induce targeted protein degradation through bifunctional molecules

US Patent 10308871 Liquid crystal compound having benzothiophene, liquid crystal composition and liquid crystal display device

US Patent 10464925 Methods to induce targeted protein degradation through bifunctional molecules

Patent Primary Examiner

The present disclosure provides compounds, compositions and methods useful for the treatment of neurodegenerative diseases, in particular synucleinopathies.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11291732 Compounds for degrading α-synuclein aggregates and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool